Wave Life Sciences Ltd (NASDAQ:WVE) shares shot up 0.9% on Tuesday . The company traded as high as $21.68 and last traded at $21.80, 6,135 shares were traded during mid-day trading. A decline of 97% from the average session volume of 199,783 shares. The stock had previously closed at $21.61.
Several research firms have issued reports on WVE. ValuEngine raised Wave Life Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Cowen reaffirmed a “hold” rating on shares of Wave Life Sciences in a report on Tuesday, July 30th. Mizuho reaffirmed a “buy” rating on shares of Wave Life Sciences in a report on Wednesday, September 25th. HC Wainwright set a $33.00 price target on Wave Life Sciences and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, Zacks Investment Research cut Wave Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. Wave Life Sciences presently has an average rating of “Hold” and an average target price of $49.50.
The company has a market cap of $705.15 million, a P/E ratio of -4.29 and a beta of 0.75. The company has a fifty day simple moving average of $21.51 and a 200-day simple moving average of $24.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.33 and a quick ratio of 2.33.
Large investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in Wave Life Sciences during the 1st quarter worth about $2,317,000. Clear Street Markets LLC purchased a new stake in Wave Life Sciences during the 2nd quarter worth about $575,000. Bailard Inc. increased its holdings in Wave Life Sciences by 97.6% during the 2nd quarter. Bailard Inc. now owns 83,000 shares of the company’s stock worth $2,165,000 after purchasing an additional 41,000 shares during the period. Aperio Group LLC purchased a new stake in Wave Life Sciences during the 2nd quarter worth about $51,000. Finally, Janus Henderson Group PLC increased its holdings in Wave Life Sciences by 16.1% during the 2nd quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock worth $88,505,000 after purchasing an additional 470,402 shares during the period. 88.84% of the stock is currently owned by institutional investors.
Wave Life Sciences Company Profile (NASDAQ:WVE)
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Recommended Story: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.